NAMA
PACB icon

Nikko Asset Management Americas’s Pacific Biosciences PACB Stock Holding History

Nikko Asset Management Americas’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.22M Sell
7,037,987
-770,593
-10% -$1.38M 0.13% 86
2025
Q4 		$14.6M Sell
7,808,580
-868,978
-10% -$1.67M 0.17% 82
2025
Q3 		$11M Sell
8,677,558
-540,897
-6% -$732K 0.11% 91
2025
Q2 		$11.3M Sell
9,218,455
-346,876
-4% -$401K 0.11% 87
2025
Q1 		$11.2M Sell
9,565,331
-613,170
-6% -$941K 0.14% 82
2024
Q4 		$18.4M Sell
10,178,501
-1,687,265
-14% -$3.29M 0.2% 72
2024
Q3 		$20.1M Sell
11,865,766
-774,795
-6% -$1.27M 0.23% 67
2024
Q2 		$17.2M Sell
12,640,561
-183,824
-1% -$371K 0.2% 71
2024
Q1 		$48M Sell
12,824,385
-375,990
-3% -$2.2M 0.48% 49
2023
Q4 		$130M Sell
13,200,375
-247,291
-2% -$2.02M 1.25% 22
2023
Q3 		$112M Sell
13,447,666
-202,282
-1% -$2.31M 1.34% 21
2023
Q2 		$181M Sell
13,649,948
-356,567
-3% -$4.33M 1.91% 16
2023
Q1 		$159M Sell
14,006,515
-159,678
-1% -$1.59M 1.84% 18
2022
Q4 		$116M Sell
14,166,193
-225,769
-2% -$1.95M 1.67% 19
2022
Q3 		$84.5M Buy
14,391,962
+46,477
+0.3% +$267K 1.08% 24
2022
Q2 		$61M Buy
14,345,485
+324,280
+2% +$1.97M 0.75% 30
2022
Q1 		$128M Buy
14,021,205
+2,106,180
+18% +$24.2M 0.94% 25
2021
Q4 		$245M Buy
11,915,025
+2,567,023
+27% +$61.9M 1.29% 24
2021
Q3 		$236M Buy
9,348,002
+1,225,930
+15% +$36.3M 1.01% 28
2021
Q2 		$284M Buy
8,122,072
+2,874,835
+55% +$83.6M 1.11% 30
2021
Q1 		$175M Buy
5,247,237
+228,099
+5% +$7.98M 0.86% 38
2020
Q4 		$130M Buy
5,019,138
+902,585
+22% +$15.3M 0.74% 45
2020
Q3 		$41.2M Buy
+4,116,553
New +$23.7M 0.37% 59
2018
Q4 		– Sell
-6,478
Closed -$36K – 150
2018
Q3 		$36K Buy
+6,478
New +$27.8K ﹤0.01% 140

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nikko Asset Management Americas's PACB Position: Q1 2026 in Review

Nikko Asset Management Americas reduced its Pacific Biosciences (PACB) stake by 9.9% in Q1 2026, selling an estimated $1.38M and leaving 7,037,987 shares worth $9.22M. The position accounts for 0.13% of the portfolio, ranked #86.

Nikko Asset Management Americas first reported a position in PACB in Q3 2018 and has held it in 24 quarters since. The position peaked at $284M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Nikko Asset Management Americas held 7,037,987 shares of Pacific Biosciences worth $9.22M as of Q1 2026.
  • Nikko Asset Management Americas sold 770,593 Pacific Biosciences shares in Q1 2026, an estimated $1.38M.
  • Pacific Biosciences made up 0.13% of Nikko Asset Management Americas's portfolio in Q1 2026, its #86 holding.
  • Nikko Asset Management Americas first reported a position in Pacific Biosciences in Q3 2018 and has held it in 24 quarters since.
  • Nikko Asset Management Americas's Pacific Biosciences position peaked at $284M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.